title: Biomarkers in psychotropic drug development.
abstract: The authors review the use of biomarkers in the development of novel psychotropic agents. They briefly review clinical drug development, emphasizing the importance of incorporating biomarkers. For the development of psychotropic agents, biomarkers are particularly useful for assessing central nervous system exposure and effects and for serving as surrogate measures for safety and efficacy. Collectively, biomarkers allow for more accurate estimation of doses for clinical trials as drug development progresses. For drugs that target the pathophysiology of Alzheimer disease, several promising biomarkers are becoming available that may allow improved signal detection in clinical trials. Procedures for developing new drugs are evolving rapidly. Technical advances in the field are making it possible to shift from empirically-based methods to mechanistically-driven schemes. Biomarkers enhance the quality and safety of clinical drug development and reduce its cost and duration.
authors.affiliation: Lily Research Laboratories, Indianapolis, Indiana, USA. ahmed_saeed@lilly.com
authors.forename: Saeeduddin
authors.initials: S
authors.lastname: Ahmed
authors.forename: P David
authors.initials: PD
authors.lastname: Mozley
authors.forename: William Z
authors.initials: WZ
authors.lastname: Potter
mesh_terms: D000368:Aged; D015415:Biomarkers; D015195:Drug Design; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D011619:Psychotropic Drugs